Research programme: protein misfolding disease therapeutics - Chaperone Therapeutics/Senhwa Biosciences

Drug Profile

Research programme: protein misfolding disease therapeutics - Chaperone Therapeutics/Senhwa Biosciences

Alternative Names: Therapeutics for proteopathies - Chaperone Therapeutics/Senhwa Biosciences

Latest Information Update: 14 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Senhwa Biosciences
  • Developer Chaperone Therapeutics; Senhwa Biosciences
  • Class Small molecules
  • Mechanism of Action Protein folding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glycogen storage disease type I; Hearing loss; Neurodegenerative disorders

Most Recent Events

  • 14 Dec 2016 Preclinical trials in Glycogen storage disease type I in USA
  • 14 Dec 2016 Preclinical trials in Hearing loss in USA
  • 04 Sep 2015 Preclinical trials in Neurodegenerative disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top